XML 25 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Net income $ 141,902 $ 114,022 $ 94,423
Adjustments to reconcile net income to net cash provided by operating activities:      
Share of profits of companies accounted for at equity, net (505) (1,535) (1,787)
Depreciation and amortization 122,184 95,507 86,932
Changes in value of debentures, net (624) (42) (2,067)
Increase (decrease) in employee benefit liabilities (220) 1,194 114
Loss (gain) from sale of property, plants and equipment (21) 118 (23)
Stock-based compensation expenses 14,767 7,779 3,874
Changes in value of short-term and long-term loans from banks and others and deposits, net 2,030 5,482 5,621
Changes in deferred taxes, net (7,997) (6,348) (13,157)
Change in liability in respect of business combinations 4,740 (643) 523
Impairment of right-of-use asset 1,439 351  
Loss (gain) from sale and increase in value of marketable securities classified as trading     35
Amortization of premium and accrued interest on debt instruments at fair value through other comprehensive income 96 (70) 82
Change in value of dividend preference derivative in TSG (255) (48) (93)
Working capital adjustments:      
Decrease (increase) in inventories 4,642 (10,966) (938)
Decrease (increase) in trade receivables (150,818) 23,312 16,265
Decrease (increase) in other current and long-term accounts receivable 20,506 8,735 12,692
Increase (decrease) in trade payables 40,076 10,954 (18,010)
Increase in other accounts payable and employees and payroll accrual 7,255 34,859 5,937
Increase in deferred revenues 9,283 4,282 5,658
Net cash provided by operating activities 208,480 286,943 196,081
Cash flows from investing activities:      
Payments for business acquisitions, net of cash acquired (Appendix C) (77,155) (141,364) (52,457)
Cash paid in conjunction with deferred payments and contingent liabilities related to business combinations (8,630) (9,111) (8,321)
Payments to former shareholders of consolidated company (161) (6,656) (996)
Purchase of intangible assets (872) (2,852) (4,399)
Purchase of other investment (500)   (178)
Purchase of property and equipment (17,352) (16,651) (22,379)
Proceeds from maturity and sale net of investment in debt instruments at fair value through other comprehensive income or loss, net   5,429 3,356
Proceeds from sale of property and equipment 2,283 693 1,660
Collection (grant) of short-term loans 303 (283) 37
Restricted deposit on account of acquisition   22,890 (22,890)
Dividend from companies accounted for at equity 83 3,000  
Change in short-term and long-term deposits, net 4,641 (22,822) 8,160
Capitalization of software development and other costs (12,832) (9,305) (9,808)
Net cash used in investing activities (110,192) (177,032) (108,215)
Cash flows from financing activities:      
Exercise of employees’ stock options in subsidiaries 2,079 5,306 953
Proceeds from issuance of ordinary shares in subsidiaries   108,737  
Dividend paid to non-controlling interests (62,993) (40,519) (37,656)
Dividend to Formula’s shareholders (22,081) (14,939) (12,966)
Short-term bank credit, net 36,261 (29,630) 49,142
Repayment of long-term loans from banks and others (84,241) (79,348) (75,548)
Receipt of long-term loans from banks and others 62,707 91,024 73,819
Proceeds from issuance of debentures, net 50,295 60,346 81,676
Repayment of long-term liabilities to office of the chief scientist (825) (457) (617)
Repayment of debentures (46,981) (29,844) (30,811)
Purchase of non-controlling interests (1,700) (6,330) (947)
Repayment of lease liabilities (44,086) (33,583) (34,500)
Cash paid due to exercise of put option by non-controlling interests (2,565) (21,030) (6,532)
Net cash provided (used) by financing activities (114,130) 9,733 6,013
Effect of exchange rate changes on cash and cash equivalents (416) 13,340 6,295
Increase (decrease) in cash and cash equivalents (16,258) 132,984 100,174
Cash and cash equivalents at beginning of year 501,650 368,666 268,492
Cash and cash equivalents at end of year 485,392 501,650 368,666
Cash paid (received) in respect of:      
Interest paid 15,344 16,571 15,733
Interest received 459 511 1,380
Taxes paid (received), net 38,393 44,659 39,063
B. Non-cash activities:      
Dividend payable to Formula’s shareholders     7,081
Purchase of property and equipment 1,627   315
Deferred and contingent payments related to business combinations 7,663 5,114 19,871
Dividend payable to non-controlling interests 331 216 1,668
Right-of-use asset recognized with corresponding lease liability 39,116 20,495 25,074
Issuance of Formula’s ordinary shares as a result of conversion of debentures     22,471
Assets and liabilities of subsidiaries consolidated as of acquisition date:      
Working capital (other than cash and cash equivalents) 1,623 (604) 1,656
Property and equipment (1,507) (13,152) (2,929)
Goodwill and intangible assets (108,048) (197,258) (98,194)
Right-of-use assets (2,401) (2,324) (1,001)
Other long-term assets (187) (8,773) (50)
Liabilities to banks and others 6,431 10,598 5,551
Long-term liabilities 1,306 13,739 2,180
Lease liabilities 2,769 2,324 1,109
Deferred tax liability, net 9,662 18,626 7,407
Liability to formerly shareholders 1,518 7,596 1,060
Deferred payments and contingent consideration 7,663 4,536 19,965
Non-controlling interests at acquisition date 4,016 23,328 5,906
Total $ (77,155) $ (141,364) $ (57,340)